Pomalidomide Approved for Refractory Myeloma

Pomalidomide has been accelerated approved by US FDA for multiple myeloma that has progressed on at least two previous therapies including bortezomib and lenalidomide, within 60 days of the last therapy. The approval was based on the multicenter, randomized, open-label study CC-4047-MM-002. The approval is based on response rates. Pomelidomide has not been as yet shown to improve survival. The combination of pomalidomide and low dose dexamethasone was resulted in a 29% response in 113 patients with one complete response and a median duration of response of 7.4 months.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.